CJC-1295
Also known as: DAC:GRF
Long-acting growth-hormone-releasing hormone analog. The DAC variant binds serum albumin to extend half-life and sustain GH/IGF-1 elevation.

- Drug class
- GHRH analog (with or without DAC)
- Primary targets
- GHRH receptor
- Dose reference
- 1–2 mg weekly (DAC, research)
- Half-life
- ~6–8 days (DAC)
- Developer / origin
- ConjuChem (original)
- Reference year
- 2005
- Evidence score
- 3/5 - Limited human pharmacology
Limited human pharmacology
CJC-1295 has human pharmacology data showing prolonged GH/IGF-1 stimulation, but it is not approved and lacks long-term outcome evidence.
Limited human pharmacology or small clinical evidence.
Evidence basis
- Human GH/IGF-1 pharmacology
- Long-acting GHRH analog data
- No approved indication
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
CJC-1295 guides
Read the matching guide or adjacent research pages for more context.
CJC-1295 calculator shortcuts
Open peptide calculators with editable CJC-1295 example values already filled in.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Ipamorelin
NNC 26-0161
Selectively stimulates pituitary growth hormone release without significant cortisol or prolactin elevation seen with older GHRPs.
Tesamorelin
Egrifta
Stabilized GHRH analog. Approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.
IGF-1 LR3
Long R3 IGF-1
A modified IGF-1 that binds IGF binding proteins far more weakly than native IGF-1, leaving it free to act as a potent, long-acting agonist at the IGF-1 receptor.
IGF-1 DES
DES(1-3) IGF-1
Removal of the N-terminal tripeptide sharply lowers IGF-binding-protein affinity while preserving IGF-1 receptor binding, leaving more free peptide to activate IGF-1R.
Category hub
Open the category page for the full comparison table and FAQ.